1 results
23/Feb/2022
23/Feb/2022
DOI: 10.31744/einstein_journal/2022RC6367
ABSTRACT Cemiplimab is a novel programmed death-1 inhibitor recently approved for advanced cutaneous squamous cell carcinoma. Immune-related adverse events derived from cemiplimab are similar to other anti-PD-1 drugs, including gastrointestinal and cutaneous toxicities. Oral immune-related adverse events were not reported with cemiplimab in previous studies; thus this case report warns of the fact that the oral cavity may be a site of immune-related adverse events during programmed death-1 block therapy and that this can lead to significant limitations when not […]
Keywords: Carcinoma, squamous cell; Immunotherapy; Oral ulcer; Skin neoplasms